콘텐츠 바로가기
부문 기준 매출액증가율 당기순이익 증가율 ROE

셀트리온

Nor-Switch 연구 결과 발표..

레미케이드와 램시마 간의 스위칭 임상 연구, 즉 Nor-Switch 연구 결과, 효능과 안전성 또는 항체 형성에서 의미있는 차이가 없다고 하네요. 

아래의 자료는 10월 18일 12:15 - 12:27에 발표될 예정입니다.


출처  https://cslide.ctimeetingtech.com/ueg2016/confcal/kvien



LB15 - BIOSIMILAR INFLIXIMAB (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFLIXIMAB: RESULTS FROM THE 52-WEEK RANDOMIZED NOR-SWITCH TRIAL


K. Jørgensen I. Olsen G. Goll M. Lorentzen N. Bolstad E. Haavardsholm K. Lundin C. Mørk J. Jahnsen T. Kvien



Introduction


TNF-inhibitors (TNFi) have improved treatment of Crohn’s disease (CD), ulcerative colitis (UC), spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and chronic plaque psoriasis (Ps). The NOR-SWITCH study was funded by the Norwegian government.



Aims & Methods


The aim of the NOR-SWITCH study was to examine switching from originator to biosimilar infliximab regarding efficacy, safety and immunogenicity. The study was designed as a 52-week randomized, double-blind, non-inferiority, phase IV trial. Adult patients with a diagnosis of CD, UC, SpA, RA, PsA or Ps on stable treatment with the originator infliximab (Remicade®, INX) for at least 6 months were eligible. Patients with informed consent were randomized 1:1 to either continued INX or switch to CT-P13 treatment (biosimilar infliximab, Remsima®), using unchanged dosing regimen. Data were collected at infusion visits. The primary endpoint was disease worsening during follow-up according to worsening in disease-specific composite measures and/or a consensus between investigator and patient leading to major change in treatment. Exploratory subgroup analyses were performed to examine disease worsening within each of the six diagnoses. The non-inferiority margin was set to 15% and power calculations indicated that 394 patients were required in the primary Per Protocol Set (PPS). The primary endpoint was analysed using logistic regression, adjusted for diagnosis and disease duration at baseline.



Results


Between October 6, 2014 and July 8, 2016, 481 patients (INX 241, CT-P13 240, Full Analysis Set, FAS) at 40 Norwegian study centres were randomized, received treatment and were followed for 52 weeks. The main demographic and baseline characteristics are shown in the table. Disease worsening occurred in 26.2% and 29.6% of patients in the INX and CT-P13 arms, respectively (PPS). The 95% confidence interval of the adjusted treatment difference (-4.4%) was -12.7 – 3.9 which was within the pre-specified non-inferiority margin. The frequency of disease worsening in each specific diagnosis is shown in the table (exploratory analyses). Changes in the generic disease variables and disease specific composite measures were similar in both arms (table). The incidence of anti-drug antibodies detected during the study was 17 (7.1%) and 19 (7.9%) in the INX and CT-P13 patients, respectively (FAS). The trough drug levels and the frequencies of reported adverse events including infusion reactions were also similar (data not shown).






Data are n (%), mean (SD) or median (25 - 75 percentiles). 95% CI, 95% confidence interval of the adjusted treatment difference. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. ASDAS, Ankylosing Spondylitis Disease Activity Score. DAS28, Disease Activity Score in 28 joints. CDAI, Clinical Disease Activity Index. SDAI, Simplified Disease Activity Index. PASI, Psoriasis Area and Severity Index.



Conclusion


The NOR-SWITCH trial demonstrated that switch from INX to CT-P13 was not inferior to continued treatment with INX.

0/1000 byte

등록

목록 글쓰기

무료 전문가 방송

  • 김희천대표

    코로나 변종출현 투심위축,기막힌 타이밍 금리인상,대응전략

    11.28 19:50 방송예정
  • 큰바다a

    100%수익 나는 주식은 패턴이있다

    11.29 15:50 방송예정
  • 진검승부

    11월 넷째 주 마감 시황 및 다음 주 투자전략

    11.26 19:00 녹화방송
전문가방송 종목입체분석/커뮤니티 상단 연계영역 전문가 배너 전문가방송 종목입체분석/커뮤니티 상단 연계영역 전문가 배너

최대 6억, 한 종목 100% 집중 투자 가능한 스탁론

최저금리 연계신용대출로 투자수익극대화
1/3

연관검색종목 11.28 12:00 기준

글쓰기